Novye vozmozhnosti v dostizhenii kompensatsii uglevodnogo obmena pri sakharnom diabete 2 tipa: yanuviya - ingibitor dipeptidilpeptidazy IV tipa
https://doi.org/10.14341/2072-0351-5360
Abstract
Янувия является первым препаратом нового класса ингибиторов ДПП-4, обладает высокой эффективностью, которая сравнима с эффектом препаратов сульфонилмочевины, применяемых для терапии СД 2. Прием янувии хорошо переносится больными, а частота развития гипогликемии идентична той, которая встречается у больных, получавших плацебо. Влияние янувии на снижение апоптоза бета-клеток и их неогенез сопровождается увеличением количества бета-клеток островков поджелудочной железы, что может замедлить или даже остановить прогрессирование СД 2 и его поздних осложнений.
About the Authors
Mikhail Ivanovich Balabolkin
ГОУ ВПО ММА им. И.М. Сеченова
Elena Michailovna Klebanova
ГОУ ВПО ММА им. И.М. Сеченова
References
1. Diabetes Control and complications trial research group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus // Arch Ophthalmol - 1995 - Vol. 113 - P. 36-51.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment of risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. - 1998. - Vol. 352. - P. 837-853.
3. UK Prospective Diabetes Study (UKPDS) Group. Effects of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) // Lancet. - 1998. - Vol. 352. - P. 854-865.
4. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complication- Part 1: Diagnosis and classification of diabetes mellitus, Geneva: WHO, 1999.
5. American Diabetes Association. Standards of medical care in diabetes // Diabetes Care - 2007 - Vol. 30 - Suppl.1, S1-S-103.
6. European Diabetes Policy Group. A desktop guide to type 2 diabetes // Diabet Med - 1999 - Vol. 16 - P. 716-730.
7. American Association of clinical endocrinologist. Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management-2002 update // Endocr Pract - 2002 - Vol. 8 - Suppl. 1 - P. 40-82.
8. Canadian Diabetes Association. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada // Can J Diabetes - 2003 - Vol. 27 - Suppl.2 - P. S1-S152.
9. Nathan D.M., Buse J.B., Davidson M.B. et al., Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy // Diabetologia - 2006 - Vol. 49 - P. 1711-1721.
10. Drucker D.J: The biology of incretin hormones. // Cell Metab. - 2006. - vol. 3. - P.153-165.
11. Deacon C. F, Carr R. D, Holst J. J. DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. // Frontiers in Bioscience. - 2008. - vol. 13. - P. 1780-1794.
12. Nauck M.A, M.M. Heimesaat, C. Orskov, J.J. Holst, R. Ebert & W. Creutzfeldt. Preserved incretin activity of glucagon-like peptide 1 [7-3 6 amide] but not of synthetic human gastric inhibitor polypeptide in patients with type-2 diabetes. // J Clin Invest. - 1993. - vol . 91. - P. 301-307.
13. Vilsboll T, T. Krarup, S. Madsbad & J.J. Holst. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. // Regul Pept. - 2003. - vol. 114. - P. 115-121.
14. Nauck M, F. Stockmann, R. Ebert & W. Creutzfeldt: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. // Diabetologia 29, 46-52 (1986).
15. Toft-Nielsen M.B, M.B. Damholt, S. Madsbad, L.M. Hilsted, T.E.Hughes, B.K. Michelsen & J.J. Holst: Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. // J Clin Endocrinol Metab 86, 3717-3723 (2001).
16. Vilsboll T, T. Krarup, C.F. Deacon, S. Madsbad & J.J. Holst: Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. // Diabetes 50, 609-613 (2001).
17. Kjems L.L, J.J. Holst, A. Volund & S. Madsbad: The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. // Diabetes 52, 380-386 (2003).
18. Vilsboll T, F.K. Knop, T. Krarup, A. Johansen, S. Madsbad, S. Larsen, T. Hansen, O. Pedersen & J.J. Holst: The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. // J Clin Endocrinol Metab 88, 4897-4903 (2003).
19. Herman G.A., Stevens C., Van Dyck K. et al., Pharmacokinetics and pharmacodynamics of sitagliptin, aninhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomised, double-blind, placebo controlled studies with single oral doses // Clin Pharmacol Ther - 2005 - Vol. 78 - P. 675-688.
20. Bergman A.J., Stevens C., Zhou Y.Y. et al., Pharmacokinetic and pharmacodynamic properties of mulpiple oral doses of sitagliptin, adipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers // Clin Ther - 2006 - Vol. 28 - P. 55-72.
21. Herman G.A., Bergman A., Liu F. et al., Pharmacokinetic and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects // J Clin Pharmacol - 2006 - V0l. 46 - P. 876-886
22. Herman G.A., Bergman A., Stevens C. et al., Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes // J Clin Endocrinol Metab - 2006 - Vol. 91- P. 4612-4619.
23. Herman G., Hanefeld M., Wu M. et al., Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor on glycaemic control after 12 weeks in patients with type 2 diabetes // Diabetes - 2005 - Vol.54 - Suppl. 1 - A134 - P. 541.
24. Scott R. Herman G., Zhao P. et al., Twelve week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor in the treatment of type 2 diabetes // Diabetes - 2005 - Vol. 54 - Suppl. 1 - A10, 41-OR.
25. Aschner P., Kipnes M.S., Lunceford J.K. et al., Sitagliptin study 021 group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycaemic control in patients with type 2 diabetes // Diabetes Care - 2006 - Vol. 29 - P. 2632-2637.
26. Brazg R., Thomas K., Zhao P. et al., Effect of adding MK-0431 to ongoing metformin therapy in type 2 diabetic patients who have inadequate glycemic control on metformin // Diabetes - 2005 - Vol. 54 - Suppl. 1 - P.A3 - 11-OR.
27. Williams-Herman D, Johnson J, Lunceford J. Initial combination therapy with sitagliptin and metformin provides effective and durable glycemic control over 1 year in patients with type 2 diabetes: a pivotal phase III clinical trial. // Poster presented at: the American Diabetes Association 67th Annual Scientific Sessions; June 22-26, 2007; Chicago, Illinois, USA.
28. Nauck M, Meininger G, Sheng D, et al, for the 024 Study Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared to the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, doubleblind, non-inferiority trial. Diabetes Obes Metab. 9, 194-205 (2007)
Review
For citations:
Balabolkin M.I., Klebanova E.M. Novye vozmozhnosti v dostizhenii kompensatsii uglevodnogo obmena pri sakharnom diabete 2 tipa: yanuviya - ingibitor dipeptidilpeptidazy IV tipa. Diabetes mellitus. 2008;11(3):43-48. (In Russ.) https://doi.org/10.14341/2072-0351-5360
Views:
2760
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
